Navigation Links
Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations
Date:4/3/2008

- Chairman and CEO Honors the Anniversary by Ringing The Closing Bell(R) at

the NYSE on April 4 -

IRVINE, Calif., April 3, 2008 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), a world leader in products and technologies to treat advanced cardiovascular disease, today announced its 50th anniversary of partnering with clinicians to develop life-saving innovations. To celebrate its five decades of innovation and success, and eight years as an independent company, Michael A. Mussallem, Edwards' chairman and CEO, will visit the New York Stock Exchange (NYSE) tomorrow afternoon to ring The Closing Bell(R), signaling the end of the trading week. A live webcast of The Closing Bell(R) will be available at http://www.nyse.com beginning at 3:55 p.m. EDT on April 4, 2008.

Edwards' 50-year history dates back to 1958, with the development of the first commercially available artificial heart valve by Miles "Lowell" Edwards and Dr. Albert Starr. The company built on this legacy by innovating a number of other pioneering products including the first -- and only -- biomechanically engineered tissue heart valve; the first heart valve repair ring; the first embolectomy catheter to remove obstructions in blood vessels; the first pulmonary artery catheter, which established the foundation for hemodynamic monitoring; and more recently, the first "beating heart" transcatheter aortic valve replacement.

"We take great pride in our 50-year heritage of working as trusted partners with clinicians to develop innovative technologies that transform patient care," said Mussallem. "We believe Lowell Edwards would be very proud of the company that bears his name today and the more than 5,600 employees worldwide who carry on his mission to provide treatments and hope for patients with advanced cardiovascular disease."

"It brings me tremendous joy that the replacement heart valves Lowell Edwards and I co-developed 50 years ago began a company that today continues to pioneer live-saving cardiovascular devices and procedures," said Dr. Albert Starr, medical director of the Providence Heart and Vascular Institute and co-recipient of a 2007 Lasker Award for the development of artificial heart valves. "I'm proud of my enduring association with Edwards Lifesciences and look forward to the company's continued success helping millions of patients worldwide."

In 1958, Lowell Edwards was a 60-year-old recently retired engineer with 63 patents in an array of industries, an entrepreneurial spirit and dreams of helping patients with heart disease. With a background in hydraulics and fuel pump operations, he believed the human heart could be mechanized. He presented the concept to Dr. Starr, a young surgeon at the University of Oregon Medical School, who encouraged Lowell Edwards to focus first on developing an artificial heart valve, for which there was an immediate need. After only two years, the first Starr-Edwards mitral valve was designed, developed, tested and successfully placed in a patient.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies. In 2008, Edwards celebrates 50 years of partnering with clinicians to develop life-saving innovations. The company's global brands, which are sold in approximately 100 countries, include CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office. The Closing Bell is a registered trademark of the New York Stock Exchange, Inc.


'/>"/>
SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lambert, Edwards & Associates Named Agency of Record for The West Michigan Science & Technology Initiative
2. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
3. Edwards Lifesciences Announces Organizational Changes
4. Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
5. Edwards Lifesciences to Host Earnings Conference Call on February 5, 2008
6. Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve
7. Edwards Lifesciences Completes Acquisition of CardioVations Product Line
8. Edwards Lifesciences Forecasts Strong Growth in 2008
9. Marshall Edwards, Inc. to Present at BIO Investor Forum 2007
10. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
11. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
Breaking Biology News(10 mins):